Pharming Group News

Pharming Group's Strategic Financial Maneuver

TipRanksApr 26 00:02

Pharming Group Lauded for Rare Disease Treatment

TipRanksApr 24 18:59

Pharming Group to Report First Quarter 2024 Financial Results on May 8

Yahoo FinanceApr 24 14:00

Pharming to Be Honored as Industry Innovator at National Organization for Rare Disorders (NORD) 2024 Rare Impact Awards

Recognition given for achievement in commercializing Joenja (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April

GlobeNewswireApr 24 13:00

Pharming Group to Buy Back EUR123 Million of Bonds Due 2025

Pharming Group (PHARM.AS) accepted 123.1 million euros of its outstanding 125 million euros of 3% senior unsecured convertible bonds due 2025 for repurchase. The Dutch biopharmaceutical company said A

MT NewswiresApr 22 13:15

Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds

Pharming Group (PHARM.AS) on Thursday launched an offering of 100 million euros of senior unsecured convertible bonds due 2029 and a repurchase offer for its outstanding 125 million euros of convertib

MT NewswiresApr 18 16:52

Optimistic Buy Rating on Pharming Group Backed by Promising Leniolisib Trials and Strategic Market Expansion

TipRanksApr 8 22:05

Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of Its Treatment for Rare Auto-Immune Disorder

Pharming Group (PHAR) said Monday it has finished enrolling 21 patients in a phase 3 clinical trial to evaluate leniolisib as a potential treatment for children aged four to 11 years old with activate

MT NewswiresApr 8 16:15

Reported Earlier, Pharming Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib

Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the completion of patient enrollment in its Phase III clinical trial (NCT05438407) evaluating the investigational drug lenioli

BenzingaApr 8 15:12

Joenja's Journey: Navigating the Market Risks and Regulatory Challenges Post-Approval for Pharming Group Nv

TipRanksApr 5 14:01

Pharming Group Files Annual Report, Sets AGM Date

TipRanksApr 4 20:57

Pharming Group to Participate in April Investor Conferences

Leiden, The Netherlands, April 3, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conferences in the month of April: 23rd Annual

GlobeNewswireApr 3 14:00

Pharming Group's Strong Performance and Growth Prospects Justify Buy Rating

TipRanksMar 18 17:05

Pharming Group N.V. (AMS:PHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

Yahoo FinanceMar 17 14:34

Pharming Group Full Year 2023 Earnings: US$0.015 Loss per Share (Vs US$0.021 Profit in FY 2022)

Yahoo FinanceMar 16 14:01

Pharming Reports Q4 Results

Seeking AlphaMar 16 03:36

Earnings Call Summary | Pharming Group(PHAR.US) Q4 2023 Earnings Conference

The following is a summary of the Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript:Financial Performance:Pharming Group reported an annual revenue of over $227 million for 2023, an increase

Futu NewsMar 15 02:11 · Conference Call

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming with a Buy and maintains $37 price target.

Analyst UpgradesMar 15 00:36

Pharming Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/14/2024 238.83% HC Wainwright & Co. → $37 Reiterates Buy → Buy 08/03/2023 238.83% HC Wainwright & Co. →

BenzingaMar 15 00:34

Pharming Group's Strong Financial Performance and Growth Potential Merit Buy Rating

TipRanksMar 14 23:35